Celgene (CELG) today announced that a European regulatory committee had issued a positive opinion on its cancer drug Revlimid. Bernstein’s Geoffrey Porges and Wen Shi explain the significance:
Boston Globe via Getty ImagesThis morning, the European Committee for Medicinal Products (CHMP) announced a positive opinion recommending the expansion of the Revlimid EU label to include front-line usage in multiple myeloma. The new indication reads “Revlimid is indicated for the continuous treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.” The positive CHMP opinion is an important step as Celgene looks to significantly expand Revlimid’s market potential in the EU. This is consistent with expectations but is not the best case scenario for Celgene since it excludes the transplant eligible population.� However, the label is not confined to the elderly or any other population subgroup, and therefore is better than the worst case scenario.
Top Telecom Stocks To Invest In Right Now: AEP Industries Inc.(AEPI)
AEP Industries Inc. engages in the production, manufacture, and distribution of plastic packaging products in the United States and Canada. The company offers a line of polyethylene, polyvinyl chloride, and polypropylene flexible packaging products for consumer, industrial, and agricultural applications. Its products include custom films for industrial applications, including sheeting, tubing, and bags; films that protect items stored outdoors or in transit, such as boats and cars; a range of shrink films, barrier films, and overwrap films; stretch film products for hand wrap and rotary applications; and pre stretch and high performance products for commodity and specialty uses. The company also provides food wraps products, including blown plastic film fold-top bags, twist-tie bags, and food containers under the Seal Wrap brand for the supermarket and industrial markets; a range of coextruded polyolefin films and monolayer films for food, pharmaceutical, and medical appli cations; and canliners product line comprising trash bags and institutional bags. In addition, it offers printed rollstock to the food and beverage industries, and manufacturing and distributing companies; and unplasticized polyvinyl chloride films for use in battery labels, twist films, and credit card laminates; and various film products with agricultural applications, such as silage, smooth mulch films, and fumigation films. Further, the company provides disposable consumer and institutional plastic products, which include table covers and skirts, aisle runners, aprons, bibs, gloves, boots, freezer/storage bags, saddle pack bags, locker wrap and custom imprint designs for the food service, party supply, and school/collegiate markets under the Sta-Dri brand. AEP Industries Inc. markets its products directly to end-users, as well as through distributors. The company was founded in 1970 and is based in South Hackensack, New Jersey.
Advisors' Opinion:- [By Lisa Levin]
AEP Industries (NASDAQ: AEPI) shares touched a new 52-week low of $34.20. AEP shares have dropped 56.11% over the past 52 weeks, while the S&P 500 index has gained 15.91% in the same period.
- [By Bryan Murphy]
It's certainly not as big as Berry Plastics Group Inc. (NYSE:BERY). It's not even as big as Tredegar Corporation (NYSE:TG). There's one big way AEP Industries (NASDAQ:AEPI) can certainly compete head-on with BERY and TG right now, however... as an investment opportunity. Thanks to the bullish bump AEPI gave us last week, a long-standing selloff has been revered, and there's a whole lot of ground to make up.
Top 5 Healthcare Technology Companies To Watch In Right Now: Schnitzer Steel Industries Inc.(SCHN)
Schnitzer Steel Industries, Inc. engages in recycling ferrous and nonferrous scrap metals, and used and salvaged vehicles; and manufacturing finished steel products. The company operates through three segments: Metals Recycling Business (MRB), Auto Parts Business (APB), and Steel Manufacturing Business (SMB). The MRB segment involves in the purchase, collection, processing, recycling, sale, and broking of ferrous scrap metals. It processes mixed and large pieces of scrap metal into smaller pieces by sorting, shearing, shredding, and torching. This segment?s products include ferrous products, including ferrous scrap metal, a feedstock used in the production of finished steel products; and nonferrous scrap metals, including aluminum, copper, stainless steel, nickel, brass, titanium, lead, high temperature alloys, and joint products, such as zorba (mixed nonferrous material) and zurik (stainless steel). The MRB segment sells its products to steel mills and smelters. The APB segment purchases used and salvaged vehicles and sells serviceable used auto parts from these vehicles through its 45 self-service auto parts stores, which are located across the United States and western Canada. It also sells other vehicles, including auto bodies; cores, such as engines, transmissions, alternators, and catalytic converters; and nonferrous materials to metal recyclers. The SMB segment engages in the purchase of recycled metal, and processing of the recycled metal and other raw materials into finished steel products. Its product portfolio comprises semi-finished goods and finished goods consisting of rebar, coiled rebar, wire rod, merchant bar, and other specialty products. This segment serves steel service centers, construction industry subcontractors, steel fabricators, wire drawers, and farm and wood product suppliers. The company exports its products worldwide. Schnitzer Steel Industries, Inc. was founded in 1946 and is based in Portland, Oregon.
Advisors' Opinion:- [By Rich Smith]
If you want to know what the future holds for global steel giants like Arcelor Mittal (NYSE: MT ) , U.S. Steel (NYSE: X ) , and Nucor (NYSE: NUE ) , one of the best ways you can spend your time, I suspect, is by reviewing the earnings reports of another company entirely -- Schnitzer Steel (NASDAQ: SCHN ) .
- [By Rich Smith]
So what's going on with Steel Dynamics? Basically, it's exactly what I warned you about last month, after reviewing the disturbing news of weak demand for steel in China, revealed by Schnitzer Steel (NASDAQ: SCHN ) in its earnings report. Steel Dynamics is hitting headwinds all around the globe:
- [By Dan Caplinger]
Another problem that ArcelorMittal and other steel companies have faced is the emerging Chinese steel industry. China subsidizes its steelmakers, and with Chinese infrastructure and construction activity being relatively weak, oversupply is spilling over and having an impact on world steel prices. Recycled scrap producer Schnitzer Steel (NASDAQ: SCHN ) noted last month that market prices for its exports fell by $50 per ton during its most recent quarter, and given Schnitzer's exposure to Asia, those figures likely reflect China's contribution to the global weakness.
Top 5 Healthcare Technology Companies To Watch In Right Now: Winthrop Realty Trust (FUR)
Winthrop Realty Trust (WRT) is a diversified real estate investment trust (REIT). WRT conducts its business through its wholly owned operating partnership, WRT Realty L.P., (the Operating Partnership).The Company is engaged in the business of owning real property and real estate related assets. The Company operates in three segments: operating properties; loan assets; and REIT securities. In June 2013, Winthrop Realty Trust sold its medical office building property located in Deer Valley, Arizona. In November 2013, Winthrop Realty Trust closed on its acquisition of four newly constructed class A luxury apartment buildings.
On May 23, 2012, the Company acquired a first mortgage loan secured by a 326,000 square foot commercial building located in Ft. Lauderdale, Florida consisted of approximately 47,000 square feet of retail and 279,000 square feet of office space that was 74.4% leased. In February 2012, Mack-Cali Realty Corporation along with WRT formed a joint venture that acquired a senior mezzanine loan position of a 1.7 million-square-foot class A portfolio in Stamford, Conn. In April 2012, it acquired a 320 unit, class A, multifamily property, situated on 27.9 acres in the Germantown/Collierville submarket of Memphis, Tennessee. On February 3, 2012, the Company acquired through its venture with Elad Canada Inc. the first mortgage loan secured by Sullivan Center, Chicago. During the year ended December 31, 2011, it acquired one investment property located in New York. On November 4, 2011, Socal Office Portfolio Loan LLC acquired first mortgage encumbering a 4,500,000 square foot, 31 property portfolios of office properties situated throughout southern California. On June 3, 2011 LW SOFI LLC acquired from Concord 100% of the economic rights and obligations in mezzanine loan collateralized by an interest in the Sofitel hotel in New York City. On June 1, 2011 it acquired, from Concord Debt Holdings LLC (Concord), senior mezzanine loan totaling 2,106 units located in Orlando, Sarasota, Bra! denton and Palm Beach Gardens, Florida. On March 22, 2011 the Company purchased through a 50/50 joint venture, two non-performing first mortgage loan. On February 23, 2011, it acquired first mortgage secured by a lien on a 26-story, 66 room limited service boutique hotel located in New York, New York through a 50/50 joint venture. On June 1, 2011 the Company sold to its partner, Marc Realty, its interest in three properties in its Marc Realty Portfolio, which included eight South Michigan, 11 East Adams and 29 East Madison.
Loan Assets
Loan assets segments includes the Company�� activities related to the origination and acquisition of senior loans, mezzanine loans and debt securities secured directly or indirectly by commercial and multi-family real property. The Company�� investment in Concord Debt Holdings LLC and CDH CDO LLC, which it refers to as the Company�� Concord investment platform, is held as an interest investment.
Operating Properties
The Company invested in a portfolio transaction, which it refers to as the Vintage portfolio. Vintage portfolio which has 25 multifamily and senior housing properties consist of 4,167 units located primarily in the Pacific Northwest and California. The average occupancy of its consolidated properties was approximately 75.1%, during 2011. As of December 31, 2011 WRT�� consolidated properties were approximately 74.2% leased. Occupancy at its Lisle, Illinois property known as 550-560 Corporetum was 61% occupied, as of December 31, 2011. At WRT�� other Lisle, Illinois property, referred to as 701 Arboretum, its major tenant, which occupied approximately 53% of the building vacated their space at the expiration of their lease term, on May 31, 2011. In addition, another tenant who occupied approximately 15% of the building vacated at the expiration of their lease, in August 2011. As a result, this property is 17% occupied, as of December 31, 2011. The Company�� 82,000 square foot Deer Valley Profes! sional Bu! ilding, located in Phoenix, Arizona was 95.6% leased, as of December 31, 2011. WRT�� Crossroads I and II buildings, which consisted of approximately 236,000 square feet, were 72.4% leased, as of December 31, 2011.
As of December 31, 2011, the Company had two tenants, Spectra Energy and Siemens Real Estate, which represented approximately 21.8% and 9.8%, respectively, of its annualized base rental revenues from consolidated commercial operating properties. As of December 31, 2011 it held interests in three real estate ventures with Sealy & Co. which had an aggregate of approximately 2,097,000 rentable square feet consisted of 18 office flex buildings and 13 light distribution and service center properties. Two of the investment properties are located in Atlanta, Georgia, (Northwest Business Park and Newmarket), which had occupancies of 77% and 52% respectively, as of December 31, 2011. As of December 31, 2011, WRT held interests in nine properties with Marc Realty, which consisted of an aggregate of approximately 1,407,000 rentable square feet of office and retail space, which was 78.5% occupied. Of the properties, in which the Company held an interest, as of December 31, 2011, two downtown Chicago properties consisted of approximately 389,000 rentable square feet of the aggregate Marc Realty portfolio. These two properties had a combined occupancy of 79.1% at December 31, 2011.
REIT Securities
The REIT securities segment includes all of the Company�� activities related the ownership of interest and debt securities in other real estate investment trusts (REITs). During 2011, it began investing again in REIT common shares, particularly in Cedar Realty Trust Inc.
Advisors' Opinion:- [By Corinne Gretler]
Fugro NV (FUR) slumped 5.8 percent to 43.90 euros, the worst performance on the Stoxx 600. The world�� biggest deepwater-oilfield surveyor said first-half earnings before interest and taxes amounted to 133 million euros, compared with 154 million euros a year earlier. Fugro said that
Top 5 Healthcare Technology Companies To Watch In Right Now: Cancer Genetics Inc (CGIX)
Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.
The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.
CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.
Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA
MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).
MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.
The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.
During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.
Urogenital cancer arrays: UroGenRA, UGenRA
The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.
UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.
UGenRA for Endometrial, Ovarian and Cervical Cancers
UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.
UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.
Advisors' Opinion:- [By RedChip]
Cancer Genetics (NASDAQ: CGIX), an emerging leader in DNA-based cancer diagnostics, priced a $15 million secondary offering and began trading on the NASDAQ today.
The offering will bring in a sizable cash infusion to CGIX, setting the stage for continued expansion of the Company�� sales and marketing efforts, as well as further product development and commercialization. In addition, it will enable the Company to fund its joint venture investment with Mayo Clinic and retire mezzanine financing.
No comments:
Post a Comment